Brief: Rhythm Pharmaceuticals Imcivree Net Revenue FY24 Expected To Be About $130 Million
10/01/2025 12:25
Jan 10 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O :
* RHYTHM PHARMACEUTICALS INC: IMCIVREE NET REVENUE FY24
EXPECTED
TO BE ABOUT $130 MILLION
* RHYTHM PHARMACEUTICALS: ON TRACK TO REPORT TOPLINE DATA
FROM
GLOBAL PHASE 3 TRIAL EVALUATING SETMELANOTIDE IN ACQUIRED
HYPOTHALAMIC OBESITY IN H1 2025
* RHYTHM PHARMACEUTICALS: PLAN TO INITIATE NEW PHASE 2 TRIAL
EXPLORING SETMELANOTIDE IN PRADER-WILLI SYNDROME
Further company coverage: RYTM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand